CAMBRIDGE, Mass. October 18, 2012 – OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that it will be attending and hosting a scientific symposium during the 68th Annual Meeting of the American Society for Reproductive Medicine (ASRM), being held October 20-24, 2012 in San Diego.
The Company’s scientific session, titled “BioEnergetics & Egg Quality: Emerging Concepts,” will include presentations by key opinion leaders in the area of infertility and will be moderated by Alan H. DeCherney, M.D., head of the Reproductive Biology and Medicine Branch of the Eunice Kennedy Shriver Institute of Child Health and Human Development at the National Institutes of Health.
“This scientific symposium will facilitate an important discussion among thought leaders in the field of infertility regarding how significant advances may lead to better outcomes for patients,” said Dr. DeCherney.
Following the conclusion of ASRM, Jonathan Tilly, Ph.D., co-founder of OvaScience, will present his research in a CME-accredited event sponsored by the Eunice Kennedy Shriver Institute of Child Health and Human Development and the ASRM. The event, titled “Ovarian Reserve: Regulation and Implications for Women’s Health,” will be held on Thursday, October 25, 2012 from 7:30 a.m. to 3:30 p.m. at the Manchester Grand Hyatt San Diego Hotel.
OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPC), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine.